Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory conditions. For many, it has provided relief when other therapies failed. However, ...

The first known lawsuit has now been filed against the makers of Dupixent (dupilumab), alleging that the popular eczema and asthma drug caused or accelerated a deadly form of lymphoma. Filed in ...

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet growing medical evidence shows that some patients ...

This add-on drug may help those with a type of lung inflammation that worsens symptoms like shortness of breath. The U.S. Food and Drug Administration has approved Dupixent (dupilumab) to reduce COPD ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 VOYAGE trial. The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to ...

TARRYTOWN, N.Y. and PARIS, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved ...

Jan 25 (Reuters) - The U.S. health regulator has approved the use of Regeneron (REGN.O), opens new tab and Sanofi's (SASY.PA), opens new tab Dupixent to treat an allergic inflammation of the esophagus ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Credit: Getty Images. The approval was based on data from a phase 3 study that evaluated Dupixent added to low potency topical corticosteroids in children aged 6 months to 5 years with uncontrolled ...